Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Non-Current Deffered Revenue (2021 - 2025)

Historic Non-Current Deffered Revenue for Autolus Therapeutics (AUTL) over the last 5 years, with Q1 2025 value amounting to $253.4 million.

  • Autolus Therapeutics' Non-Current Deffered Revenue rose 1091.63% to $253.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was $253.4 million, marking a year-over-year increase of 1091.63%. This contributed to the annual value of $244.6 million for FY2024, which is 4312.55% up from last year.
  • Per Autolus Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $253.4 million for Q1 2025, which was up 1091.63% from $244.6 million recorded in Q4 2024.
  • Autolus Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $253.4 million during Q1 2025, with a 5-year trough of $47.0 million in Q4 2021.
  • Its 5-year average for Non-Current Deffered Revenue is $151.2 million, with a median of $138.3 million in 2023.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first skyrocketed by 16844.0% in 2023, then surged by 1091.63% in 2025.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Non-Current Deffered Revenue stood at $47.0 million in 2021, then soared by 167.78% to $125.9 million in 2022, then surged by 35.74% to $170.9 million in 2023, then surged by 43.13% to $244.6 million in 2024, then rose by 3.61% to $253.4 million in 2025.
  • Its Non-Current Deffered Revenue stands at $253.4 million for Q1 2025, versus $244.6 million for Q4 2024 and $248.9 million for Q3 2024.